Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521178 | 0.89 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL20168992 | 0.85 | MMP2 (0.32) | — | |
| SCHEMBL20169007 | 0.84 | CHRM1 (0.38) | ALDH1A1KMT2AMEN1GAANPC1 | |
| SCHEMBL20969153 | 0.83 | ADAMTS5 (0.50) | LIPE | |
| SCHEMBL20969156 | 0.82 | CHRM3 (0.40) | KMT2AMEN1NPC1POLBHSD17B10 | |
| SCHEMBL19521218 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL19521216 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL19521243 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL19541656 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL19521194 | 0.77 | L3MBTL3 (0.38) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | SLC1A2, SLC1A1, SLC7A11 | ALDH1A1 885/4885KMT2A 2772/4885MEN1 4431/4885 |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | SLC1A2, SLC1A1, SLC7A11 | ALDH1A1 1035/4885KMT2A 3108/4885MEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.